Jew Olivia S, Provini Lauren E, Treat James R
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Pediatr Dermatol. 2019 Jan;36(1):e62-e63. doi: 10.1111/pde.13720. Epub 2018 Nov 26.
Vemurafenib, a selective BRAF kinase inhibitor, has been found to induce several cutaneous adverse effects, ranging from a keratosis pilaris-like reaction to squamous cell carcinoma. While photosensitivity has been well described as one of these manifestations, we report a case of a 6-year-old boy on vemurafenib who developed a severe blistering sunburn after only two 30-minute episodes of sun exposure. A brief review of other common cutaneous adverse effects of vemurafenib is also provided.
维莫非尼是一种选择性BRAF激酶抑制剂，已发现它会引发多种皮肤不良反应，从毛发角化病样反应到鳞状细胞癌不等。虽然光敏反应已被详细描述为其中一种表现，但我们报告了一例6岁男孩使用维莫非尼的病例，该男孩仅在两次每次30分钟的日晒后就出现了严重的水疱性晒伤。本文还简要回顾了维莫非尼其他常见的皮肤不良反应。
